Cabaletta Bio, Inc. (CABA) NASDAQ
3.25
-0.26(-7.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.25
-0.26(-7.41%)
Currency In USD
| Previous Close | 3.51 |
| Open | 3.47 |
| Day High | 3.51 |
| Day Low | 3.21 |
| 52-Week High | 4.23 |
| 52-Week Low | 1.26 |
| Volume | 4.27M |
| Average Volume | 3.08M |
| Market Cap | 529.93M |
| PE | -1.83 |
| EPS | -1.78 |
| Moving Average 50 Days | 3.3 |
| Moving Average 200 Days | 2.67 |
| Change | -0.26 |
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with a
Cabaletta Bio Announces 2026 Strategic Priorities
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automate